The growing biosimilars opportunity.
How to navigate EU regulatory complexity and maximise the market potential.
Biosimilars are important, cost-effective alternatives to biological medicines, improving patient access to modern therapy – especially for the treatment of serious pathological conditions including cancer, neurodegenerative and autoimmune diseases.
As these therapeutic alternatives become trusted and more widely used by clinicians, and as more patents and market exclusivity linked to innovator products expire, the range and volumes of biosimilars will only grow.
As more biological products lose their exclusivity, there is likely to be a race to bring biosimilars to market and companies which hold back could lose significant ground.
